DS 109Alternative Names: DGLA - second generation; Dihomogammalinolenic-acid - second generation; DS 109A; DS109
Latest Information Update: 17 Jan 2017
At a glance
- Originator Dignity Sciences
- Developer DS Biopharma
- Class Eicosanoids; Omega-6 fatty acids; Skin disorder therapies; Small molecules; Unsaturated fatty acids
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Skin disorders
- Preclinical Unspecified